methyl 4-(6-hydroxyhexyl)benzoate | 222983-66-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-(6-hydroxyhexyl)benzoate
• CAS: 222983-66-6
• 化学式: C₁₄H₂₀O₃
• 分子量: 236.311
• InChiKey: MDSZQEWMILOOLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  Methyl 4-[(1E)-6-hydroxy-1-hexene-1-yl]benzoate 在 palladium-carbon 氩 、 氢气 、 silica gel 、 正己烷 、 乙酸乙酯 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以to obtain methyl 4-(6-hydroxyhexyl)benzoate (2.22 g)的产率得到methyl 4-(6-hydroxyhexyl)benzoate
  参考文献：
  名称：

  Compound containing basic group and use thereof

  摘要：

  本发明涉及一种化合物，其表示为公式(I-0)：其中，公式中的符号与本说明书中所描述的含义相同，其盐、N-氧化物或溶剂化物或前药，以及其医药用途。本发明的化合物具有对CXCR4的拮抗活性，因此可用作CXCR4介导疾病的预防和/或治疗剂，例如，炎症和免疫性疾病（例如，类风湿性关节炎、关节炎、视网膜病变、肺纤维化、移植器官排斥等）、过敏性疾病、感染（例如，人类免疫缺陷病毒感染、获得性免疫缺陷综合症等）、神经精神疾病、脑部疾病、心血管疾病、代谢性疾病和癌症性疾病（例如，癌症、癌症转移等），或再生治疗剂。

  公开号：

  US08822459B2

文献信息

• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR
  申请人：Arvinas, Inc.

  公开号：US20180099940A1

  公开（公告）日：2018-04-12

  The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

  本公开涉及双功能化合物，其用于降解和（抑制）雄激素受体。具体而言，本公开涉及包含一端结合到E3泛素连接酶的谷氨酰腺苷环配体，另一端结合到雄激素受体的部分的化合物，使得雄激素受体与泛素连接酶靠近，以实现雄激素受体的降解（和抑制）。本公开展示了与根据本公开涉及的化合物相关的广泛的药理活性范围，与雄激素受体的降解/抑制一致。
• [EN] COMPOUND CONTAINING BASIC GROUP AND USE THEREOF<br/>[FR] COMPOSÉ CONTENANT UN GROUPE BASIQUE ET UTILISATION
  申请人：ONO PHARMACEUTICAL CO

  公开号：WO2006022454A1

  公开（公告）日：2006-03-02

  A compound represented by the general formula (I-0): (I-0) (wherein the symbols are as defined in the description), a salt thereof, N-oxide form thereof, or solvate thereof, or a prodrug of any of these; and a medicinal use of these. The compound has CXCR4 antagonistic activity and is hence useful, e.g., as a preventive and/or therapeutic agent for CXCR4-mediated diseases, e.g., inflammatory/immunologic diseases (e.g., articular rheumatism, arthritis, retinopathy, pulmonary fibrosis, and rejection reactions against transplanted organs), allergic diseases, infectious diseases (e.g., human immunodeficiency virus infection and acquired immunological deficiency syndrome), mental/nervous diseases, brain diseases, cardiac/vascular diseases, metabolic diseases, and carcinomatous diseases (e.g., cancers and cancer metastasis), or as an agent for regenerative medicine.

  一种由通式(I-0):(I-0)表示的化合物（其中符号如描述中所定义），其盐，N-氧化物形式，或溶剂合物，或这些的前药；以及这些的药用。该化合物具有CXCR4拮抗活性，因此可用作预防和/或治疗CXCR4介导的疾病，例如炎症/免疫疾病（例如关节风湿病，关节炎，视网膜病变，肺纤维化和对移植器官的排斥反应），过敏疾病，传染病（例如人类免疫缺陷病毒感染和获得性免疫缺陷综合症），精神/神经疾病，脑疾病，心脏/血管疾病，代谢疾病以及癌症疾病（例如癌症和癌症转移），或作为再生医学的药物。
• [EN] GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES<br/>[FR] ANTAGONISTE DES RECEPTEURS DU GLUCAGON, PREPARATION ET UTILISATIONS THERAPEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2005123668A1

  公开（公告）日：2005-12-29

  The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

  本发明公开了具有胰高血糖素受体拮抗剂或逆拮抗剂活性的化合物I的新化合物，或其药用可接受的盐，以及制备这些化合物的方法。在另一实施例中，本发明公开了包含化合物I的药物组合物，以及使用它们治疗糖尿病和其他与胰高血糖素相关的代谢性疾病等方法。
• Compound Containing Basic Group and Use Thereof
  申请人：Kokubo Masaya

  公开号：US20080009495A1

  公开（公告）日：2008-01-10

  The present invention relates to a compound represented by formula (I-0): wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

  本发明涉及一种由式（I-0）表示的化合物：其中，式中的符号与本说明书中所述的意义相同，其盐，N-氧化物或溶剂化物或其前药，以及其医学用途。本发明的化合物具有对CXCR4的拮抗活性，因此可用作预防和/或治疗CXCR4介导的疾病的药物，例如，炎症和免疫性疾病（例如，类风湿性关节炎，关节炎，视网膜病变，肺纤维化，移植器官排斥等），过敏性疾病，感染（例如，人类免疫缺陷病毒感染，获得性免疫缺陷综合症等），精神神经疾病，脑部疾病，心血管疾病，代谢性疾病和癌症性疾病（例如，癌症，癌症转移等），或作为再生疗法的药物。
• COMPOUND CONTAINING BASIC GROUP AND USE THEREOF
  申请人：KOKUBO Masaya

  公开号：US20110142856A1

  公开（公告）日：2011-06-16

  The present invention relates to a compound represented by formula (I-0): wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoidarthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

  本发明涉及一种由式（I-0）表示的化合物：其中式中的符号具有本说明书中所述的相同含义，其盐、N-氧化物或溶剂化物或前药，以及其医药用途。本发明的化合物具有对CXCR4的拮抗活性，因此可用作预防和/或治疗CXCR4介导的疾病的药物，例如，炎症和免疫性疾病（例如，类风湿性关节炎，关节炎，视网膜病变，肺纤维化，移植器官排斥等），过敏性疾病，感染（例如，人类免疫缺陷病毒感染，获得性免疫缺陷综合症等），精神神经疾病，脑部疾病，心血管疾病，代谢性疾病和癌症性疾病（例如，癌症，癌症转移等），或用于再生疗法的药物。